glycine has been researched along with HPV Infection in 3 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The importance of PIK3CA alterations in squamous cell carcinoma of the head and neck (HNSCC) has raised interest in exploring agents targeting PI3K, the product of PIK3CA." | 1.39 | The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas. ( Aisner, DL; Anderson, RT; Astling, DP; Bowles, DW; Eagles-Soukup, J; Frederick, BA; Gan, GN; Glogowska, MJ; Jimeno, A; Keysar, SB; Le, P; Morton, JJ; Sehrt, D; Takimoto, SM; Tan, AC; Umpierrez, A; Varella-Garcia, M; Vogler, BW; Wilhelm, F, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, RT | 1 |
| Keysar, SB | 1 |
| Bowles, DW | 1 |
| Glogowska, MJ | 1 |
| Astling, DP | 1 |
| Morton, JJ | 1 |
| Le, P | 1 |
| Umpierrez, A | 1 |
| Eagles-Soukup, J | 1 |
| Gan, GN | 1 |
| Vogler, BW | 1 |
| Sehrt, D | 1 |
| Takimoto, SM | 1 |
| Aisner, DL | 1 |
| Wilhelm, F | 1 |
| Frederick, BA | 1 |
| Varella-Garcia, M | 1 |
| Tan, AC | 1 |
| Jimeno, A | 1 |
| Prasad, A | 1 |
| Khudaynazar, N | 1 |
| Tantravahi, RV | 1 |
| Gillum, AM | 1 |
| Hoffman, BS | 1 |
| Chan, PK | 1 |
| Lam, CW | 1 |
| Cheung, TH | 1 |
| Li, WW | 1 |
| Lo, KW | 1 |
| Chan, MY | 1 |
| Cheung, JL | 1 |
| Cheng, AF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of Oral Rigosertib in Patients With Relapsed or Metastatic, Platinum-resistant, Human Papillomavirus Positive or Negative Squamous Cell Carcinoma[NCT01807546] | Phase 2 | 64 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for glycine and HPV Infection
| Article | Year |
|---|---|
The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas.
Topics: Carcinoma, Squamous Cell; Cell Cycle Proteins; Class I Phosphatidylinositol 3-Kinases; Glycine; Head | 2013 |
ON 01910.Na (rigosertib) inhibits PI3K/Akt pathway and activates oxidative stress signals in head and neck cancer cell lines.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival | 2016 |
Association of human papillomavirus type 58 variant with the risk of cervical cancer.
Topics: Adult; Alanine; Base Sequence; Cysteine; Female; Genetic Variation; Glycine; Hong Kong; Humans; Midd | 2002 |